|
Dear [Preferred Customer Name]:
|
| Email Opener 0 |
|
Thank you for taking the time to speak with me about Orenitram® (treprostinil) Extended-Release Tablets—the only oral prostacyclin analogue for pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity.
|
| Email Opener 1 |
|
I am glad we got the chance to talk about Orenitram® (treprostinil) Extended-Release Tablets—the only oral prostacyclin analogue for pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity.
|
| Email Opener 2 |
|
Sorry I missed you. I wanted to share some information about Orenitram® (treprostinil) Extended-Release Tablets—the only oral prostacyclin analogue for pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity.
|
| Please refer to the Important Safety Information provided below. |
| Setup/Offering |
Because some of your patients may benefit from a prostacyclin-class therapy,
I wanted to send this reminder:
I wanted to share the following:
I wanted to follow up and let you know:
I thought you may want to review some highlights:
|
Because there were a few points we did not get to discuss,
I wanted to send this reminder:
I wanted to share the following:
I wanted to follow up and let you know:
I thought you may want to review some highlights:
|
Because you had asked me a question about Orenitram,
I wanted to send this reminder:
I wanted to share the following:
I wanted to follow up and let you know:
I thought you may want to review some highlights:
|
Since we did not get a chance to review this information in person,
I wanted to send this reminder:
I wanted to share the following:
I wanted to follow up and let you know:
I thought you may want to review some highlights:
|
| Email Fragments(multi-optional) |
|
|
| Closing 0 |
|
I hope you will consider prescribing Orenitram for your next PAH patient who could benefit from a prostacyclin-class therapy.
|
| Closing 1 |
|
I hope you will continue using Orenitram for your PAH patients in the future.
|
| Closing 2 |
|
I hope you will think about whether any more of your PAH patients are candidates for Orenitram.
|
| Closing 3 |
|
I look forward to our next meeting.
|
|
If you have any questions about Orenitram, would like to request additional materials, or would like to schedule a convenient time to meet, please contact me via the email/phone number provided below.
|
| Signoffs |
|
Sincerely,
|
|
Best regards,
|
|
Have a great day!
|
|
[Representative Name]
|
|
[Email Address]
|
|
[Phone]
|
|
INDICATION
|
|
Orenitram is a prostacyclin vasodilator indicated for treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity.
|
|
The study that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or
heritable PAH (75%) or PAH associated with connective tissue disease (19%). When used as the sole vasodilator, the effect of Orenitram on exercise is
about 10% of the deficit, and the effect, if any, on a background of another vasodilator is probably less than this.
|
|
IMPORTANT SAFETY INFORMATION FOR ORENITRAM
|
|
CONTRAINDICATIONS
|
- Orenitram is contraindicated in patients with severe hepatic impairment (Child Pugh Class C)
|
|
WARNINGS AND PRECAUTIONS
|
- Abrupt discontinuation or sudden large reductions in dosage of Orenitram may result in worsening of PAH symptoms
- Orenitram inhibits platelet aggregation and increases the risk of bleeding
- The Orenitram tablet shell does not dissolve. In patients with diverticulosis, Orenitram tablets can lodge in a diverticulum
|
|
DRUG INTERACTIONS/SPECIFIC POPULATIONS
|
- Concomitant administration of Orenitram with diuretics, antihypertensive agents, or other vasodilators increases the risk of symptomatic hypotension
- Orenitram inhibits platelet aggregation; there is an increased risk of bleeding, particularly among patients receiving anticoagulants
- Co-administration of Orenitram and the CYP2C8 enzyme inhibitor gemfibrozil increases exposure to treprostinil; therefore, Orenitram dosage reduction may be necessary in these patients
- Pregnancy Category C. Animal reproductive studies with Orenitram have shown an adverse effect on the fetus. There are no adequate and well-controlled studies in humans
- It is not known whether treprostinil is excreted in human milk or absorbed systemically after ingestion. Because many drugs are excreted in human milk, choose Orenitram or breastfeeding
- Safety and effectiveness in patients under 18 years of age have not been established
- There is a marked increase in the systemic exposure to treprostinil in hepatically impaired patients
|
|
ADVERSE REACTIONS
|
- In the 12-week placebo-controlled monotherapy study, adverse reactions that occurred at rates at least 5% higher on Orenitram than on placebo included headache, diarrhea, nausea, flushing, pain in jaw, pain in extremity, hypokalemia, and abdominal discomfort
|
|
OREISIhcpJAN16
|
|
|
Please see the Full Prescribing Information and Patient Information for Orenitram.
|
To learn more about how to use Orenitram, REQUEST A REP or call
1-877-UNITHER (1-877-864-8437).
|
|
Orenitram is a registered trademark of United Therapeutics Corporation.
|
© 2016 United Therapeutics Corporation. All rights reserved.
XXXXCODEXXX |